SC-43
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


SC-43
Description :
SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects[1][2].UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Apoptosis; Phosphatase; SHP1; STATType :
Reference compoundRelated Pathways :
Apoptosis; JAK/STAT Signaling; Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK; Stem Cell/WntApplications :
Cancer-Kinase/proteaseField of Research :
CancerAssay Protocol :
https://www.medchemexpress.com/sc-43.htmlPurity :
99.01Solubility :
DMSO : 250 mg/mL (ultrasonic)Smiles :
O=C(NC1=CC=CC(OC2=CC=C(C#N)C=C2)=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3Molecular Formula :
C21H13ClF3N3O2Molecular Weight :
431.80Precautions :
H302, H315, H319, H335References & Citations :
[1]Ming-Hung Hu, et al. Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. Oncotarget. 2017 May 10;8 (39) :65077-65089.|[2]Tung-Hung Su, et al. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis. Sci Rep. 2017 May 11;7 (1) :1728.Shipping Conditions :
Room TemperatureStorage Conditions :
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category :
Reference compound1Clinical Information :
Phase 2Isoform :
STAT3CAS Number :
[1400989-25-4]

